• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

revance therapeutics

  1. A wrinkle for Allergan; Botox competitor reports positive data

    Revance Therapeutics reports positive data for RT002. http://alph.st/b96326ac A threat to Allergan's Botox, which accounted for 19% of total revenue in Allergan's recently ended quarter.
    • anonymous
    • Thread
    • allergan botox revance therapeutics
    • Replies: 3
    • Forum: Allergan
Top Bottom
Back